- Japan
- /
- Healthcare Services
- /
- TSE:2934
J FrontierLtd Full Year 2024 Earnings: JP¥426 loss per share (vs JP¥410 loss in FY 2023)
J FrontierLtd (TSE:2934) Full Year 2024 Results
Key Financial Results
- Revenue: JP¥17.7b (up 5.2% from FY 2023).
- Net loss: JP¥2.09b (loss widened by 9.8% from FY 2023).
- JP¥426 loss per share (further deteriorated from JP¥410 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
J FrontierLtd shares are down 19% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 2 warning signs for J FrontierLtd (1 is potentially serious!) that you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:2934
J FrontierLtd
Engages in the healthcare sale, medical care sale, and healthcare marketing businesses in Japan.
Slightly overvalued with imperfect balance sheet.
